Wegener's Granulomatosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus; Psoriasis; Behcet's Disease; Wegener's Granulomatosis; Takayasu's Disease; Crohn's Disease; Ulcerative Colitis; Autoimmune Hepatitis; Sclerosing CholangitisIntervention: Drug: Interleukin 2Sponsors: Assistance Publique - Hôpitaux de Paris; ILTOO PharmaRecruiting - verified January 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2013 Category: Research Source Type: clinical trials

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus; Psoriasis; Behcet's Disease; Wegener's Granulomatosis; Takayasu's Disease; Crohn's Disease; Ulcerative Colitis; Autoimmune Hepatitis; Sclerosing CholangitisIntervention: Drug: Interleukin 2Sponsors: Assistance Publique - Hôpitaux de Paris; ILTOO PharmaRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2013 Category: Research Source Type: clinical trials

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis; Wegener Granulomatosis; VasculitisInterventions: Drug: 5 mg prednisone; Drug: 0 mg prednisoneSponsors: University of South Florida; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); National Center for Advancing Translational Science (NCATS); Rare Diseases Clinical Research NetworkRecruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2013 Category: Research Source Type: clinical trials

A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Wegener's Granulomatosis, Microscopic PolyangiitisIntervention: Drug: rituximab [MabThera/Rituxan]Sponsor: Hoffmann-La RocheRecruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2012 Category: Research Source Type: clinical trials